Leadership Team

NGT BioPharma Consultants Leadership Team

Our team is comprised of drug development industry experts and problem-solvers providing strategic solutions for the biopharmaceutical industry. The leadership team works closely with 160+ top-tier consultants and professionals across the entire drug development spectrum.

Michael K. O’Brien, PhD
President & CEO
Mark A. Krook, PhD
Head of Early Drug Development

Angie Christoffersen, BS, MBA

Head of Strategy, Marketing and Business Development

Daniel Schaufelberger, PhD
Head of Pediatric Center of Excellence
Roger Nosal, MA
Head of Global Regulatory Strategy and Submissions
Ronay LeBlanc, MA
Head of Quality & Compliance
Jim Weber, PhD
Head of CMC Biologics
Edward Herpel NGT BioPharma Consultants
Ed Herpel, MA
Head of Business Effectiveness
Michelle McGuinness, MS
Head of Non-CMC Regulatory Strategy
Michael Placke, PhD, DABT
Michael Placke, PhD, DABT
Head of Nonclinical Sciences
Michael J. Neeb, PhD
Head of Discovery & Investigative Research
 
Rachel Franckowiak, BA
Head of Administration
Malcolm Berry, PhD - Multi-Stage Continuous Processing for APIs
 
Malcolm Berry, PhD
API Continuous Processing

Nancy C. Motola, PhD, RAC
Regulatory, Compliance, Quality Assurance
Michael Placke, NGT Biopharma Consultants
 
Michael Placke, PhD, DABT
Nonclinical Development
and Drug Safety

Leo Adalbert, NGT BioPharma Consultants

 
Leo J. Adalbert
Principal Consultant –
Strategic Commercialization

 
John L. Dillon, PhD
API Process R&D, Synthetic Organic Chemistry
 
Jeff Brum, PhD
Pharmaceutical Analysis – CMC Product Development

Robert Dennehy, PhD
API Crystallization and Solid State
 
Steve Hammond
Process Analytics and
PAT Innovator
 
Paul E. Luner, PhD
Oral Formulation Development & Physical Pharmaceutics
 
Frank P. Orlowski, MBA
Biotech and Life Sciences
Global Finance
 
Douglas Nesta, PhD
Chemistry, Manufacturing & Controls
 
Mike Webb, PhD
Chemistry, Manufacturing & Controls